Fig. 9.

Differences in CCL12, CCL2, and TGFβ cannot explain the differential ability of γHV-68, but not H1N1, to exacerbate ECM deposition post-bleomycin. Mice were treated with bleomycin on day 0 and infected with saline, γHV-68, or H1N1 on day 14. On day 21, lungs were harvested and whole lung homogenates were analyzed by ELISA for CCL12 (A), CCL2 (B), levels of active (C, left side) or acid-activated total TGFβ (C, right side). n = 3–5 mice/group representative of 2 experiments. *P < 0.05. **P < 0.01.